Mnk2 Alternative Splicing Modulates the p38-MAPK Pathway and Impacts Ras-Induced Transformation

Cell Reports

Volumn 7, Issue 2, 2014, Pages 501-513

  Maimon, Avraham ^a   Mogilevsky, Maxim ^a   Shilo, Asaf ^a   Golan Gerstl, Regina ^a   Obiedat, Akram ^a   Ben Hur, Vered ^a   Lebenthal Loinger, Ilana ^a   Stein, Ilan ^a   Reich, Reuven ^b   Beenstock, Jonah ^b   Zehorai, Eldar ^c   Andersen, Claus L ^d   Thorsen, Kasper ^d   Ørntoft, Torben F ^d   Davis, Roger J ^e   Davidson, Ben ^f,g   Mu, David ^h   Karni, Rotem ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF OSLO   (Norway)

^h EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE P38; MNK2A PROTEIN; MNK2B PROTEIN; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN; UNCLASSIFIED DRUG; MKNK2 PROTEIN, MOUSE; PROTEIN BINDING;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST TUMOR; CELL DEATH; CELL NUCLEUS; CELL TRANSFORMATION; COLON TUMOR; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GENE TRANSLOCATION; IN VITRO STUDY; IN VIVO STUDY; LUNG TUMOR; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ACTIVE TRANSPORT; ANIMAL; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ALTERNATIVE SPLICING; ANIMALS; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; MAP KINASE SIGNALING SYSTEM; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RAS PROTEINS;

EID: 84899619503     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.03.041     Document Type: Article

References (54)

1. Adesso L., Calabretta S., Barbagallo F., Capurso G., Pilozzi E., Geremia R., Delle Fave G., Sette C. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 2013, 32:2848-2857.
2. Anczuków O., Rosenberg A.Z., Akerman M., Das S., Zhan L., Karni R., Muthuswamy S.K., Krainer A.R. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat. Struct. Mol. Biol. 2012, 19:220-228.
3. Aplin A.E., Hogan B.P., Tomeu J., Juliano R.L. Cell adhesion differentially regulates the nucleocytoplasmic distribution of active MAP kinases. J.Cell Sci. 2002, 115:2781-2790.
4. Askari N., Diskin R., Avitzour M., Capone R., Livnah O., Engelberg D. Hyperactive variants of p38alpha induce, whereas hyperactive variants of p38gamma suppress, activating protein 1-mediated transcription. J.Biol. Chem. 2007, 282:91-99.
5. Avitzour M., Diskin R., Raboy B., Askari N., Engelberg D., Livnah O. Intrinsically active variants of all human p38 isoforms. FEBS J. 2007, 274:963-975.
6. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., Griswold D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J.Pharmacol. Exp. Ther. 1996, 279:1453-1461.
7. Bae J., Leo C.P., Hsu S.Y., Hsueh A.J. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J.Biol. Chem. 2000, 275:25255-25261.
8. Benhar M., Dalyot I., Engelberg D., Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol. Cell. Biol. 2001, 21:6913-6926.
9. Ben-Hur V., Denichenko P., Siegfried Z., Maimon A., Krainer A., Davidson B., Karni R. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep. 2013, 3:103-115.
10. Brancho D., Tanaka N., Jaeschke A., Ventura J.J., Kelkar N., Tanaka Y., Kyuuma M., Takeshita T., Flavell R.A., Davis R.J. Mechanism of p38 MAP kinase activation invivo. Genes Dev. 2003, 17:1969-1978.
11. Chrestensen C.A., Shuman J.K., Eschenroeder A., Worthington M., Gram H., Sturgill T.W. MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines. J.Biol. Chem. 2007, 282:4243-4252.
12. Cuadrado A., Nebreda A.R. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 2010, 429:403-417.
13. Das S., Anczuków O., Akerman M., Krainer A.R. Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep. 2012, 1:110-117.
14. De Nicola G.F., Martin E.D., Chaikuad A., Bassi R., Clark J., Martino L., Verma S., Sicard P., Tata R., Atkinson R.A., et al. Mechanism and consequence of the autoactivation of p38α mitogen-activated protein kinase promoted by TAB1. Nat. Struct. Mol. Biol. 2013, 20:1182-1190.
15. Diskin R., Askari N., Capone R., Engelberg D., Livnah O. Active mutants of the human p38alpha mitogen-activated protein kinase. J.Biol. Chem. 2004, 279:47040-47049.
16. Diskin R., Lebendiker M., Engelberg D., Livnah O. Structures of p38alpha active mutants reveal conformational changes in L16 loop that induce autophosphorylation and activation. J.Mol. Biol. 2007, 365:66-76.
17. Enslen H., Raingeaud J., Davis R.J. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J.Biol. Chem. 1998, 273:1741-1748.
18. Ferreiro I., Joaquin M., Islam A., Gomez-Lopez G., Barragan M., Lombardía L., Domínguez O., Pisano D.G., Lopez-Bigas N., Nebreda A.R., Posas F. Whole genome analysis of p38 SAPK-mediated gene expression upon stress. BMC Genomics 2010, 11:144.
19. Fukunaga R., Hunter T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 1997, 16:1921-1933.
20. Furic L., Rong L., Larsson O., Koumakpayi I.H., Yoshida K., Brueschke A., Petroulakis E., Robichaud N., Pollak M., Gaboury L.A., et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl. Acad. Sci. USA 2010, 107:14134-14139.
21. Ge K., DuHadaway J., Du W., Herlyn M., Rodeck U., Prendergast G.C. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc. Natl. Acad. Sci. USA 1999, 96:9689-9694.
22. Gong X., Ming X., Deng P., Jiang Y. Mechanisms regulating the nuclear translocation of p38 MAP kinase. J.Cell. Biochem. 2010, 110:1420-1429.
23. Hazzalin C.A., Cano E., Cuenda A., Barratt M.J., Cohen P., Mahadevan L.C. p38/RK is essential for stress-induced nuclear responses: JNK/SAPKs and c-Jun/ATF-2 phosphorylation are insufficient. Curr. Biol. 1996, 6:1028-1031.
24. Hossini A.M., Geilen C.C., Fecker L.F., Daniel P.T., Eberle J. A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain. Oncogene 2006, 25:2160-2169.
25. Hu S.I., Katz M., Chin S., Qi X., Cruz J., Ibebunjo C., Zhao S., Chen A., Glass D.J. MNK2 inhibits eIF4G activation through a pathway involving serine-arginine-rich protein kinase in skeletal muscle. Sci. Signal. 2012, 5:ra14.
26. Itoh M., Nelson C.M., Myers C.A., Bissell M.J. Rap1 integrates tissue polarity, lumen formation, and tumorigenic potential in human breast epithelial cells. Cancer Res. 2007, 67:4759-4766.
27. Karni R., de Stanchina E., Lowe S.W., Sinha R., Mu D., Krainer A.R. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 2007, 14:185-193.
28. Kim E., Goren A., Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet. 2008, 24:7-10.
29. Knauf U., Tschopp C., Gram H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol. Cell. Biol. 2001, 21:5500-5511.
30. Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., Adams J.L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000, 47:185-201.
31. MacNeil A.J., Jiao S.C., McEachern L.A., Yang Y.J., Dennis A., Yu H., Xu Z., Marshall J.S., Lin T.J. MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer. Cancer Res. 2014, 74:162-172.
32. Mamane Y., Petroulakis E., Rong L., Yoshida K., Ler L.W., Sonenberg N. eIF4E-from translation to transformation. Oncogene 2004, 23:3172-3179.
33. Parra J.L., Buxadé M., Proud C.G. Features of the catalytic domains and C termini of the MAPK signal-integrating kinases Mnk1 and Mnk2 determine their differing activities and regulatory properties. J.Biol. Chem. 2005, 280:37623-37633.
34. Parra-Palau J.L., Scheper G.C., Wilson M.L., Proud C.G. Features in the N and C termini of the MAPK-interacting kinase Mnk1 mediate its nucleocytoplasmic shuttling. J.Biol. Chem. 2003, 278:44197-44204.
35. Pfundt R., van Vlijmen-Willems I., Bergers M., Wingens M., Cloin W., Schalkwijk J. In situ demonstration of phosphorylated c-jun and p38 MAP kinase in epidermal keratinocytes following ultraviolet B irradiation of human skin. J.Pathol. 2001, 193:248-255.
36. Plotnikov A., Zehorai E., Procaccia S., Seger R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim. Biophys. Acta 2011, 1813:1619-1633.
37. Rincón M., Davis R.J. Regulation of the immune response by stress-activated protein kinases. Immunol. Rev. 2009, 228:212-224.
38. Sakurai T., Kudo M., Umemura A., He G., Elsharkawy A.M., Seki E., Karin M. p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. Cancer Res. 2013, 73:215-224.
39. Scheper G.C., Parra J.L., Wilson M., Van Kollenburg B., Vertegaal A.C., Han Z.G., Proud C.G. The N and C termini of the splice variants of the human mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and localization. Mol. Cell. Biol. 2003, 23:5692-5705.
40. Shenberger J.S., Zhang L., Hughlock M.K., Ueda T., Watanabe-Fukunaga R., Fukunaga R. Roles of mitogen-activated protein kinase signal-integrating kinases 1 and 2 in oxidant-mediated eIF4E phosphorylation. Int. J. Biochem. Cell Biol. 2007, 39:1828-1842.
41. Shimoni-Sebag A., Lebenthal-Loinger I., Zender L., Karni R. RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation. Carcinogenesis 2013, 34:2498-2504.
42. Srebrow A., Kornblihtt A.R. The connection between splicing and cancer. J.Cell Sci. 2006, 119:2635-2641.
43. Srinivasula S.M., Ahmad M., Guo Y., Zhan Y., Lazebnik Y., Fernandes-Alnemri T., Alnemri E.S. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Res. 1999, 59:999-1002.
44. Steinman H.A., Burstein E., Lengner C., Gosselin J., Pihan G., Duckett C.S., Jones S.N. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J.Biol. Chem. 2004, 279:4877-4886.
45. Turjanski A.G., Vaqué J.P., Gutkind J.S. MAP kinases and the control of nuclear events. Oncogene 2007, 26:3240-3253.
46. Ueda T., Watanabe-Fukunaga R., Fukuyama H., Nagata S., Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol. Cell. Biol. 2004, 24:6539-6549.
47. Ueda T., Sasaki M., Elia A.J., Chio I.I., Hamada K., Fukunaga R., Mak T.W. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc. Natl. Acad. Sciences USA 2010, 107:13984-13990.
48. Venables J.P. Aberrant and alternative splicing in cancer. Cancer Res. 2004, 64:7647-7654.
49. Venables J.P., Klinck R., Koh C., Gervais-Bird J., Bramard A., Inkel L., Durand M., Couture S., Froehlich U., Lapointe E., et al. Cancer-associated regulation of alternative splicing. Nat. Struct. Mol. Biol. 2009, 16:670-676.
50. Wakeman D., Schneider J.E., Liu J., Wandu W.S., Erwin C.R., Guo J., Stappenbeck T.S., Warner B.W. Deletion of p38-alpha mitogen-activated protein kinase within the intestinal epithelium promotes colon tumorigenesis. Surgery 2012, 152:286-293.
51. Waskiewicz A.J., Flynn A., Proud C.G., Cooper J.A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 1997, 16:1909-1920.
52. Wendel H.G., Silva R.L., Malina A., Mills J.R., Zhu H., Ueda T., Watanabe-Fukunaga R., Fukunaga R., Teruya-Feldstein J., Pelletier J., Lowe S.W. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007, 21:3232-3237.
53. Worch J., Tickenbrock L., Schwäble J., Steffen B., Cauvet T., Mlody B., Buerger H., Koeffler H.P., Berdel W.E., Serve H., Müller-Tidow C. The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells. Oncogene 2004, 23:9162-9172.
54. Xi L., Feber A., Gupta V., Wu M., Bergemann A.D., Landreneau R.J., Litle V.R., Pennathur A., Luketich J.D., Godfrey T.E. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res. 2008, 36:6535-6547.